Neratinib is a TFEB and TFE3 activator that potentiates autophagy and unbalances energy metabolism in ERBB2+ breast cancer cells.
暂无分享,去创建一个
K. Cortese | P. Castagnola | M. Gagliani | M. Matteoli | Paola Falletta | P. Rusmini | P. Arnaldi | G. Bellese | S. Santamaria | E. Tagliatti
[1] K. Cortese,et al. Imaging Endocytosis Dynamics in Health and Disease , 2022, Membranes.
[2] Min Hwan Kim,et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.
[3] E. Reiman,et al. Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43 , 2021, Aging.
[4] K. Cortese,et al. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells , 2021, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[5] F. Grossi,et al. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors , 2021, International journal of molecular sciences.
[6] J. Guan,et al. Autophagy inhibition perturbs ERBB2 trafficking and abolishes tumorigenesis in ERBB2-driven breast cancer , 2021, Autophagy.
[7] Y.-Z. Dai,et al. TFEB Biology and Agonists at a Glance , 2021, Cells.
[8] H. Rugo,et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. , 2020, Clinical breast cancer.
[9] Shujun Wang,et al. Emerging role of transcription factor EB in mitochondrial quality control. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[10] P. Dent,et al. Not the comfy chair! Cancer drugs that act against multiple active sites , 2019, Expert opinion on therapeutic targets.
[11] D. Tuveson,et al. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells , 2019, Oncogene.
[12] J. Crown,et al. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer , 2019, Cancers.
[13] K. Cortese,et al. The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2+ breast cancer cells , 2019, Biology Open.
[14] K. Cortese,et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration , 2018, Autophagy.
[15] R. Amaravadi,et al. Targeting autophagy in cancer , 2018, Cancer.
[16] Hesham K. Yosef,et al. Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells , 2018, Angewandte Chemie.
[17] P. Dent,et al. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells , 2018, Cancer biology & therapy.
[18] J. Kirkwood,et al. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib , 2017, Cancer biology & therapy.
[19] M. Sardiello,et al. AKT modulates the autophagy-lysosome pathway via TFEB , 2017, Cell cycle.
[20] K. Cortese,et al. Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells , 2017, Oncotarget.
[21] J. Neilson,et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases , 2017, Nature Communications.
[22] K. Cortese,et al. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells , 2016, Oncotarget.
[23] Han Liu,et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. , 2016, Cancer letters.
[24] J. Luzio,et al. Endolysosomes Are the Principal Intracellular Sites of Acid Hydrolase Activity , 2016, Current Biology.
[25] T. Agatsuma,et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.
[26] M. Buyse,et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.
[27] Yubin Li,et al. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia , 2015, Autophagy.
[28] D. Meek,et al. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters , 2014, Nucleic acids research.
[29] Yuan Zhang,et al. Autophagy stimulates apoptosis in HER2‐overexpressing breast cancers treated by lapatinib , 2013, Journal of cellular biochemistry.
[30] Ira Mellman,et al. Endocytosis and cancer. , 2013, Cold Spring Harbor perspectives in biology.
[31] M. Duffy,et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer , 2013, Oncotarget.
[32] K. Cortese,et al. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments , 2013, Molecular biology of the cell.
[33] A. Ballabio,et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB , 2012, The EMBO journal.
[34] R. Cancedda,et al. The nuclear genes Mtfr1 and Dufd1 regulate mitochondrial dynamic and cellular respiration , 2010, Journal of cellular physiology.
[35] Ashutosh Kumar Singh,et al. A Non-canonical MEK/ERK Signaling Pathway Regulates Autophagy via Regulating Beclin 1* , 2009, The Journal of Biological Chemistry.
[36] N. Hynes,et al. ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.
[37] R. Cancedda,et al. Impaired expression of genes coding for reactive oxygen species scavenging enzymes in testes of Mtfr1/Chppr-deficient mice. , 2007, Reproduction.
[38] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[39] Yosef Yarden,et al. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.